A study conducted between August 2017 and April 2019 with 288 participants for hepatitis C virus (HCV) treatment evaluated the impact of a digital medicine program (DMP) on medication adherence (Proteus Digital Health) in a population at risk for nonadherence.
The study was a prospective, single-arm, open-label study at 18 US academic and community clinics. All participants had at least one risk factor for non-adherence, and the majority of patients studied had Medicaid coverage (64.92%) and psychiatric disorders (61.1%).
- HCV cure (ie. SVR) was achieved in 99.1% of 218 participants who received direct-acting antivirals for 8-12 weeks, used the DMP and had SVR assessed at ≥10 weeks post-treatment
- Overall pill-taking adherence was 95.0% (57.1%, 100%)
- Participants rated the system as useful and easy to use through satisfaction surveys
This is promising data for digital pills. etectRx’s ID-Cap™ System is another solution that can assist in the fight for adherence in populations at high risk for nonadherence. Watch the ID-Cap™ demo to see our technology.
Treatment adherence is critical to obtaining HCV cure with these antivirals, especially in vulnerable populations, and to achieving the goal of World Health Organizations eliminating HCV as a public health threat by 2030.